1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Genetic Testing Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of genetic and oncology disorders and need for precision medicine
5.1.1.2. Government initiatives for genetic testing and rise of self-test kits
5.1.2. Restraints
5.1.2.1. Concerns associated with false positives & negatives of genetic tests
5.1.3. Opportunities
5.1.3.1. Ongoing research and new developments in genetic testing technologies
5.1.3.2. Emergence of genetic testing with telehealth and digital health platforms
5.1.4. Challenges
5.1.4.1. Logistical barriers and privacy concerns to genetic testing
5.2. Market Segmentation Analysis
5.2.1. Product: Penetration of software and services for efficient data management and analysis
5.2.2. Test Type: Emphasis on diagnostic testing to perform particular disease dignosis
5.2.3. Technology: Increasing shift toward DNA sequencing for precise gene identification and disease diagnosis
5.2.4. Application: Rising adoption of genetic testing to detect early signs of cancer
5.2.5. Distribution Channel: Deployment of genetic testing products on online platforms
5.2.6. End-User: Extensive use of genetic testing solutions in hospitals & clinics for disease diagnosis and treatment planning
5.3. Market Trend Analysis
5.3.1. Technological advances and presence of established pharmaceutical companies enhance the genetic testing market growth in the Americas
5.3.2. Increasing chronic disorders and expanding healthcare infrastructure supports genetic testing in the APAC region.
5.3.3. Government initiatives and increasing demand for personalized medicine expand genetic testing market growth in the EMEA region.
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
6. Genetic Testing Market, by Product
6.1. Introduction
6.2. Consumables & Equipment
6.3. Software & Services
7. Genetic Testing Market, by Test Type
7.1. Introduction
7.2. Carrier Testing
7.3. Diagnostic Testing
7.4. New Born Screening
7.5. Pharmacogenomics
7.6. Preimplantation Testing
7.7. Prenatal Testing
7.8. Presymptomatic & Predictive Testing
8. Genetic Testing Market, by Technology
8.1. Introduction
8.2. Cytogenetics
8.3. DNA Sequencing
8.4. Gene Expression Profiling
8.5. Microarrays
8.6. PCR
9. Genetic Testing Market, by Application
9.1. Introduction
9.2. Autoimmune Disorders
9.3. Cancer
9.4. Chronic Diseases
9.5. Genetic Disorders
9.6. Neurodegenerative Diseases
10. Genetic Testing Market, by Distribution Channel
10.1. Introduction
10.2. Offline
10.3. Online
11. Genetic Testing Market, by End-User
11.1. Introduction
11.2. Diagnostic Laboratories
11.3. Home Setting
11.4. Hospitals & Clinics
12. Americas Genetic Testing Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Genetic Testing Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Genetic Testing Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.2. Market Share Analysis, By Key Player
15.3. Competitive Scenario Analysis, By Key Player
15.3.1. Merger & Acquisition
15.3.1.1. Sema4 to acquire genetic testing firm GeneDx for USD 623 Million
15.3.1.2. healthŌme Acquires Kailos Genetics
15.3.1.3. Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research
15.3.2. Agreement, Collaboration, & Partnership
15.3.2.1. Scribe and Sanofi expand genetic therapy development deal
15.3.2.2. CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
15.3.2.3. Invitae Announces Partnership with Epic to Streamline Genetic Testing
15.3.3. New Product Launch & Enhancement
15.3.3.1. Devyser launches two new genetic testing solutions for hereditary cancer
15.3.3.2. Blueprint Genetics introduces the new Screening Tests family; giving actionable insights for family planning, and future health
15.3.3.3. Kindbody Brings Genetic Testing In-House with the Launch of Kindlabs
15.3.3.4. PathogenDx Expands Reach of Its Patented Multiplexed Molecular Testing Technology, Bringing It to the Clinical, Food and Agriculture Sectors
15.3.4. Investment & Funding
15.3.4.1. DNA company Asa Ren raises USD 8M and more briefs
15.3.4.2. Genetic Testing Firm Delve Gets USD 35 Million in VC Funding
15.3.5. Award, Recognition, & Expansion
15.3.5.1. FBI approves QIAGEN’s NGS-based ForenSeq MainstAY workflow for the U.S. National DNA Index System (NDIS)
15.3.5.2. MapMyGenome launches India’s First DNA Test For Personalized Skin And Hair Care
15.3.5.3. Grand Launching Of DNATEST.ID, A Comprehensive Dna Test In Indonesia
15.3.5.4. MyHeritage Releases cM Explainer to Predict Familial Relationships Between DNA Matches with Greater Accuracy
16. Competitive Portfolio
16.1. Key Company Profiles
16.1.1. Abbott Laboratories
16.1.2. Agilent Technologies, Inc.
16.1.3. Becton, Dickinson and Company
16.1.4. Bio-Rad Laboratories, Inc.
16.1.5. Blueprint Genetics Oy
16.1.6. Centogene N.V.
16.1.7. Color Health, Inc.
16.1.8. CooperSurgical Inc.
16.1.9. Editas Medicine, Inc.
16.1.10. ELITechGroup SAS
16.1.11. Eugene Labs Pty Ltd.
16.1.12. Eurofins Scientific SE
16.1.13. F. Hoffmann-La Roche AG
16.1.14. Fulgent Genetics, Inc.
16.1.15. Gene by Gene, Ltd.
16.1.16. GeneDx, LLC
16.1.17. Illumina, Inc.
16.1.18. Invitae Corporation
16.1.19. Laboratory Corporation of America Holdings
16.1.20. Living DNA Ltd.
16.1.21. Macrogen, Inc.
16.1.22. MyHeritage Ltd.
16.1.23. Myriad Genetics, Inc.
16.1.24. Natera, Inc.
16.1.25. Newtopia Inc.
16.1.26. PathogenDx Corporation
16.1.27. PerkinElmer Inc.
16.1.28. Qiagen N.V.
16.1.29. Sanofi S.A.
16.1.30. Thermo Fisher Scientific Inc.
16.2. Key Product Portfolio
17. Appendix
17.1. Discussion Guide
17.2. License & Pricing
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
